News about "antibody-drug conjugates "

Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer

Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.

Antibody-Drug Conjugates | 10/08/2026 | By News Bureau

Iksuda Therapeutics Secures US FDA IND Clearance for Novel ADC Candidate IKS04 in GI Cancers

Phase 1 trial to evaluate first-of-its-kind CA242-targeted antibody-drug conjugate with an innovative co-administration regimen designed to improve solid tumour penetration and therapeutic efficacy.

Antibody-Drug Conjugates | 03/08/2026 | By News Bureau

Piramal Pharma Solutions Expands ADC Capabilities with Ajinomoto Bio-Pharma Services Pact

Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to accelerate ADC development and manufacturing, enabling access to AJICAP technology.

Antibody Drug Conjugates | 20/04/2026 | By News Bureau |  183

Mycenax and Spera Pharma Partner to Streamline ADC Drug Substance and Drug Product Manufacturing Services

The partnership aims to speed up market entry for biopharma firms by combining Mycenax's biologics expertise with Spera Pharma’s high-potent fill-finish capabilities, offering an integrated, cost-effective ADC development platform.

Antibody-Drug Conjugates | 15/09/2025 | By Dineshwori |  334

Veranova's Devens Site Clears FDA Inspection with Zero Observations

Veranova's Devens site has successfully completed a routine current Good Manufacturing Practice (cGMP) surveillance inspection by the Food and Drug Administration (FDA).

Antibody-drug Conjugates | 14/08/2025 | By Dineshwori |  356

Veranova Names Thomas Rohrer as Vice President of Bioconjugation

Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation.

Antibody Drug Conjugates | 29/07/2025 | By Dineshwori |  325

Curia Plans Expansion to Global Network of Sterile Fill-Finish Sites

Curia’s sterile fill-finish facility in Glasgow will add an integrated, isolator-based vial filling line and lyophilizer suitable for a broad range of drug product including highly potent capabilities, more than doubling current GMP batch size.

Antibody Drug Conjugates | 18/03/2025 | By Aishwarya |  705

Novo Holdings Invests in Series A Launch Financing for Callio Therapeutics

The oversubscribed Series A financing was led by Frazier Life Sciences, with significant participation from Novo Holdings and other life sciences investors including Jeito Capital, Omega Funds, Norwest, ClavystBio, EDBI, Platanus, Pureos Bioventures and SEEDS Capital.

Antibody-drug Conjugates | 04/03/2025 | By Aishwarya |  750

Lantern Pharma Launches Innovative AI-Powered Module to Advance ADC Development for Cancer

The global ADC market is projected to reach USD 30.4 billion by 2028, growing at a CAGR of 41.7 percent, with several recently approved ADCs achieving blockbuster status with annual sales exceeding USD 1 billion.

Antibody-drug Conjugates | 28/01/2025 | By Aishwarya |  599

NJ Bio Partners with Charles River to Accelerate ADC Development

The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs.

Antibody Drug Conjugates | 08/11/2024 | By Aishwarya |  335